KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Accured Expenses (2017 - 2025)

Twist Bioscience (TWST) has disclosed Change in Accured Expenses for 9 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 351.08% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 63.27% year-over-year, with the annual reading at $6.6 million for FY2025, 49.76% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $1.5 million at Twist Bioscience, down from $3.2 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $8.5 million in Q2 2024, with the low at -$3.7 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is $1.0 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses crashed 935.06% in 2022, then soared 411.67% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $445000.0 in 2021, then plummeted by 935.06% to -$3.7 million in 2022, then skyrocketed by 58.88% to -$1.5 million in 2023, then skyrocketed by 60.67% to -$601000.0 in 2024, then surged by 351.08% to $1.5 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $1.5 million, $3.2 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.